Decoding 12 Analyst Evaluations For Halozyme Therapeutics
Decoding 12 Analyst Evaluations For Halozyme Therapeutics
解读奥洛兹美医疗的12项分析师评估
Throughout the last three months, 12 analysts have evaluated Halozyme Therapeutics (NASDAQ:HALO), offering a diverse set of opinions from bullish to bearish.
过去三个月，12位分析师对Halozyme Therapeutics（NASDAQ: HALO）进行了评估，提供了从看涨到看跌的各种观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他们最近的评级概况，突出了过去30天内情绪的变化，并将其与之前的月份进行了比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $55.0, a high estimate of $71.00, and a low estimate of $50.00. Witnessing a positive shift, the current average has risen by 1.63% from the previous average price target of $54.12.
分析团队12个月的价格目标给出了一些观点，其中包括平均目标价为55.0美元，最高估值为71.0美元，最低估值为50.00美元。当前平均目标价比上一个54.12美元的平均目标价上涨了1.63%。
Investigating Analyst Ratings: An Elaborate Study
分析师评级的调查：一项详尽的研究
A comprehensive examination of how financial experts...
最近分析师行动...
登录免费看全文
登录/注册